Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology

November 20, 2017 Misidentified Cell Lines: The Scale of the Problem and How to Avoid It Cell lines have been the cornerstone of life science research for decades. Yet they’ve been misidentified and misused almost as long as they’ve been in existence. Some staggering figures exist: the German DSMZ cell repository at one time reported that 18% of its human cell line stocks were cross-contaminated with other cell lines. LEARN MORE
November 10, 2017 EORTC 2017 Short Talk Review Transcriptomic Analysis of Patient-Derived Xenografts Reveals Heterogeneity in Human and Mouse Stroma/Immune ... LEARN MORE
November 8, 2017 Humanized Mouse Clinical Trials for Immunotherapy Development Recent posts have covered the different types of mouse clinical trial (MCT) and which is most suited to any given drug ... LEARN MORE
November 3, 2017 Using PDX as Surrogate Models for TME Investigation The diversity of cancers is due to the fact that there are numerous different types, along with many different ... LEARN MORE
October 31, 2017 How to Choose the Right Type of Mouse Clinical Trial As covered in our recent blog post, Mouse Clinical Trials using patient-derived xenograft (PDX) models provide more ... LEARN MORE
October 26, 2017 Post FDA Approval: CAR-T Therapy Key Facts A few weeks ago, the FDA issued a historic approval of the first cancer cell therapy using a chimeric antigen receptor ... LEARN MORE
October 24, 2017 Top 5 Reasons To Use Mouse Clinical Trials Preclinical oncology drug development needs new tools and approaches. Current methods result in 95% attrition rates for cancer agents in clinical trials due to a lack of efficacy, even though the potential drugs looks highly promising in preclinical testing. LEARN MORE
October 19, 2017 Quick Guide: Top 3 AML Approval Trends for 2017 Acute myeloid leukemia has been the focus of much drug development, but few drug approvals, for the past few decades. ... LEARN MORE
October 12, 2017 Organ-on-a-Chip: The Future of Improved Drug Discovery? I’m a firm believer in the use of animal models in medical research. This is so for many reasons. A chemist and mentor ... LEARN MORE
October 5, 2017 What's Next for Immune Checkpoint Inhibitors: TIM-3? Unlike negative regulators, such as PD-1 and CTLA-4 (which have been proposed as therapeutic targets in different ... LEARN MORE
October 3, 2017 First Stable, Serially Transplantable M5 AML PDX Model Published It is traditionally difficult to develop stable blood cancer patient-derived xenograft (PDX) models. Historically, commercially available models have been transient and non-transferable through passages. This only allows one-shot studies providing a gross measure of response, not suitable for efficacy studies. LEARN MORE
September 26, 2017 Epigenetic Inhibitors: Strategies to Enhance Patient Response to Immunotherapy Major breakthroughs in the treatment of patients with multiple types of cancer have been achieved by drugs targeting ... LEARN MORE
September 21, 2017 Blood Cancer PDX Models: Focus on Acute Myeloid Leukemia‎ A number of our previous posts have covered the benefits of patient-derived xenografts (PDX), usually focusing on ... LEARN MORE
September 19, 2017 Beginners Guide: Humanized Drug Target Immuno-Oncology Models Our recent post compared stable vs transiently humanized models, which are needed when human-specific therapeutics are ... LEARN MORE
September 12, 2017 CD137: An Important Target in T Cell Co-Stimulation Following on from OX40, our TNF superfamily posts continue with CD137, another important target in T cell ... LEARN MORE